It is known that CFTR (cystic fibrosis transmembrane conductance regulator) modulators improve lung diseases associated with cystic fibrosis (CF). However, the effects of CFTR therapies on structural changes in the lungs of CF patients are unclear. US researchers therefore wanted to determine the effects on clinical parameters and structural lung disease, as measured by changes in chest CT scans, in people with CF.
This content is machine-translated. Please contact us if you need professional translation services.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Journal Club
Atopic dermatitis and the skin microbiome: new study findings
- AID systems for type 1 diabetes
New real-world data shows: AI makes the difference
- Derma-oncology
Current study results underline the risk of skin cancer
- Vaccines against pneumococci, influenza & RSV
Avoid exacerbations with the vaccination
- Rehospitalization
Analysis of unplanned readmissions to acute care hospitals.
- Cardiorenal syndrome
Cross-talk between heart and kidney
- Suspicion of coronary heart disease
Stress echocardiography, MR heart or computed tomography heart?
- Chronic urticaria